Pharmacology of adriamycin: the message to the clinician.
Pharmacology of adriamycin: the message to the clinician.
复制标题
阿霉素的药理学：给临床医生的信息。
DOI：
10.1016/0277-5379(88)90283-0
复制
发表时间：
1988
期刊：
影响因子：
--
通讯作者：
J. Smyth
中科院分区：
文献类型：
--
作者：
J. Cummings;J. Smyth
在试图描述ADR的人体药理学时，人们意识到我们知识的差距和现有数据的不足。然而，如果我们能够将体外观察结果合理地转化为临床药理学效应，或者解释为什么没有产生预期的效应，这些信息是必不可少的。迄今为止的临床药代动力学研究表明，ADR血液浓度与毒性之间存在明确的关系。ADR血液水平与治疗反应之间没有这种关系。ADR的7-脱氧糖苷配基组织代谢物也出现在血液中，可能与ADR的心脏毒性更密切相关，因此可能提供其发展的更好的药代动力学标志物。似乎唯一准确的药代动力学反应指标是肿瘤本身的药物水平。
In attempting to describe the human pharmacology of ADR, one is aware of the gaps in our knowledge and shortcomings of the available data. Nevertheless, such information is essential if we are ever to be able to convert rationally in vitro observations into clinical pharmacologic effect or, as is more often the case, explain why the desired effect has not been produced. Clinical pharmacokinetic studies to-date suggest that there is a clear relationship between ADR blood levels and toxicity. No such relationship between ADR blood levels and therapeutic response has been shown. The 7-deoxyaglycone tissue metabolites of ADR, which also appear in blood, may be more closely related to ADR cardiotoxicity and therefore may provide a better pharmacokinetic marker of its development. It appears that the only accurate pharmacokinetic indicator of response is the level of drug in the tumour itself.
阿霉素对 L1210 小鼠白血病细胞胞内钙浓度的影响。
DOI：
10.1016/0277-5379(87)90073-3
发表时间：
1987
期刊：
European journal of cancer & clinical oncology
影响因子：
--
作者：
Keyes,SR;Hickman,JA;Sartorelli,AC
通讯作者：
Sartorelli,AC